ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy

(2018) Timothy M. Pierpont et al.   Frontiers in Oncology

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

(2017) Pieternella Lugtenburg et al.   HAEMATOLOGICA

Update on the use of immunoglobulin in human disease: A review of evidence

(2017) Elena E. Perez et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

(2017) Pieternella Lugtenburg et al.   HAEMATOLOGICA

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

(2017) Andrew Davies et al.   Lancet Haematology

Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability

(2016) Richard L Wasserman et al.   Immunotherapy

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

(2016) Richard L. Wasserman et al.   JOURNAL OF CLINICAL IMMUNOLOGY

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer

(2016) Erwin De Cock et al.   Cancer Medicine

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial

(2016) Sarit Assouline et al.   Lancet Haematology

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

(2015) Sanna Rosengren et al.   AAPS Journal

Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy

(2015) H. Michael Shepard   Frontiers in Oncology

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

(2014) C. Jackisch et al.   ANNALS OF ONCOLOGY

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

(2014) X. Pivot et al.   ANNALS OF ONCOLOGY

Subcutaneous immunoglobulin: facilitated infusion and advances in administration

(2014) R. L. Wasserman   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers

(2014) Samuel S. Dychter et al.   CLINICAL THERAPEUTICS

Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies

(2014) Richard L Wasserman   Immunotherapy

Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study

(2014) Antonio Salar et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

(2014) Andrew Davies et al.   LANCET ONCOLOGY

Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom

(2014) Simon Rule et al.   JOURNAL OF MEDICAL ECONOMICS

A Randomized Clinical Trial of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Versus Intravenous Rehydration in Mild to Moderately Dehydrated Children in the Emergency Department

(2012) Philip R. Spandorfer et al.   CLINICAL THERAPEUTICS

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase

(2012) L. Morrow et al.   DIABETES CARE

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

(2012) Richard L. Wasserman et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

(2012) Richard L. Wasserman   JOURNAL OF CLINICAL IMMUNOLOGY

Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer

(2012) Chris Wynne et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Reduction in Intrasubject Variability in the Pharmacokinetic Response to Insulin After Subcutaneous Co-Administration with Recombinant Human Hyaluronidase in Healthy Volunteers

(2011) Linda Morrow et al.   Diabetes Technology & Therapeutics

Use of Recombinant Human Hyaluronidase to Accelerate Rapid Insulin Analogue Absorption: Experience with Subcutaneous Injection and Continuous Infusion

(2011) Daniel Vaughn et al.   Endocrine Practice

Accelerated Pharmacokinetics and Glucodynamics of Prandial Insulins Injected With Recombinant Human Hyaluronidase

(2009) Daniel E. Vaughn et al.   Diabetes Technology & Therapeutics

Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management

(2009) Amber L Dunn et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The INFUSE-Morphine IIB Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneous Morphine in Healthy Volunteers

(2009) Jay R. Thomas et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients with Advanced Illness

(2009) Jay R. Thomas et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT